Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tobias Kratina is active.

Publication


Featured researches published by Tobias Kratina.


Molecular Cell | 2008

To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions.

Grant Dewson; Tobias Kratina; Huiyan W. Sim; Jerry M. Adams; Peter M. Colman; Ruth M. Kluck

The Bcl-2 relative Bak is thought to drive apoptosis by forming homo-oligomers that permeabilize mitochondria, but how it is activated and oligomerizes is unclear. To clarify these pivotal steps toward apoptosis, we have characterized multiple random loss-of-function Bak mutants and explored the mechanism of Bak conformation change during apoptosis. Single missense mutations located to the alpha helix 2-5 region of Bak, with most altering the BH3 domain or hydrophobic groove (BH1 domain). Loss of function invariably corresponded to impaired ability to oligomerize. An essential early step in Bak activation was shown to be exposure of the BH3 domain, which became reburied in dimers. We demonstrate that oligomerization involves insertion of the BH3 domain of one Bak molecule into the groove of another and may produce symmetric Bak dimers. We conclude that this BH3:groove interaction is essential to nucleate Bak oligomerization, which in turn is required for its proapoptotic function.


Molecular Cell | 2009

Bak Activation for Apoptosis Involves Oligomerization of Dimers via Their α6 Helices

Grant Dewson; Tobias Kratina; Peter E. Czabotar; Catherine L. Day; Jerry M. Adams; Ruth M. Kluck

A pivotal step toward apoptosis is oligomerization of the Bcl-2 relative Bak. We recently reported that its oligomerization initiates by insertion of an exposed BH3 domain into the groove of another Bak monomer. We now report that the resulting BH3:groove dimers can be converted to the larger oligomers that permeabilize mitochondria by an interface between alpha6 helices. Cysteine residues placed in alpha6 could be crosslinked only after apoptotic signaling. Cysteines placed at both interfaces established that the BH3:groove dimer is symmetric and that the alpha6:alpha6 interface can link these dimers into homo-oligomers containing at least 18 Bak molecules. A putative zinc-binding site in alpha6 was not required to form the alpha6:alpha6 interface, and its mutation in full-length Bak did not affect Bak conformation, oligomerization, or function. We conclude that alpha6:alpha6 interaction occurs during Bak oligomerization and proapoptotic function, but we find no evidence that zinc binding to that interface regulates apoptosis.


Cell Death & Differentiation | 2012

Bax dimerizes via a symmetric BH3:groove interface during apoptosis

Grant Dewson; Stephen Ma; Paul Frederick; Colin Hockings; Iris K. L. Tan; Tobias Kratina; Ruth M. Kluck

During apoptotic cell death, Bax and Bak change conformation and homo-oligomerize to permeabilize mitochondria. We recently reported that Bak homodimerizes via an interaction between the BH3 domain and hydrophobic surface groove, that this BH3:groove interaction is symmetric, and that symmetric dimers can be linked via the α6-helices to form the high order oligomers thought responsible for pore formation. We now show that Bax also dimerizes via a BH3:groove interaction after apoptotic signaling in cells and in mitochondrial fractions. BH3:groove dimers of Bax were symmetric as dimers but not higher order oligomers could be linked by cysteine residues placed in both the BH3 and groove. The BH3:groove interaction was evident in the majority of mitochondrial Bax after apoptotic signaling, and correlated strongly with cytochrome c release, supporting its central role in Bax function. A second interface between the Bax α6-helices was implicated by cysteine linkage studies, and could link dimers to higher order oligomers. We also found that a population of Bax:Bak heterodimers generated during apoptosis formed via a BH3:groove interaction, further demonstrating that Bax and Bak oligomerize via similar mechanisms. These findings highlight the importance of BH3:groove interactions in apoptosis regulation by the Bcl-2 protein family.


Cell Death & Differentiation | 2007

Identification of mammalian mitochondrial proteins that interact with IAPs via N-terminal IAP binding motifs

Anne M. Verhagen; Tobias Kratina; Christine J. Hawkins; John Silke; Paul G. Ekert; David L. Vaux

Direct IAP binding protein with low pI/second mitochondrial activator of caspases, HtrA2/Omi and GstPT/eRF3 are mammalian proteins that bind via N-terminal inhibitor of apoptosis protein (IAP) binding motifs (IBMs) to the baculoviral IAP repeat (BIR) domains of IAPs. These interactions can prevent IAPs from inhibiting caspases, or displace active caspases, thereby promoting cell death. We have identified several additional potential IAP antagonists, including glutamate dehydrogenase (GdH), Nipsnap 3 and 4, CLPX, leucine-rich pentatricopeptide repeat motif-containing protein and 3-hydroxyisobutyrate dehydrogenase. All are mitochondrial proteins from which N-terminal import sequences are removed generating N-terminal IBMs. Whereas most of these proteins have alanine at the N-terminal position, as observed for previously described antagonists, GdH has an N-terminal serine residue that is essential for X-linked IAP (XIAP) interaction. These newly described IAP binding proteins interact with XIAP mainly via BIR2, with binding eliminated or significantly reduced by a single point mutation (D214S) within this domain. Through this interaction, many are able to antagonise XIAP inhibition of caspase 3 in vitro.


Journal of Biological Chemistry | 2013

Assembly of the Bak Apoptotic Pore A CRITICAL ROLE FOR THE BAK PROTEIN α6 HELIX IN THE MULTIMERIZATION OF HOMODIMERS DURING APOPTOSIS

Stephen Ma; Colin Hockings; Khatira Anwari; Tobias Kratina; Stephanie Fennell; Michael Lazarou; Michael T. Ryan; Ruth M. Kluck; Grant Dewson

Background: Bak and Bax form pores that damage mitochondria during apoptosis. Results: Under native conditions, the basic oligomeric unit of Bak is a BH3:groove homodimer that requires the α6 helix to multimerize and mediate cell death. Conclusion: Bak forms pores via two independent requisite interfaces. Significance: Characterizing Bak pores will facilitate inhibition of damaging apoptosis, e.g. in ischemic stroke. Bak and Bax are the essential effectors of the intrinsic pathway of apoptosis. Following an apoptotic stimulus, both undergo significant changes in conformation that facilitates their self-association to form pores in the mitochondrial outer membrane. However, the molecular structures of Bak and Bax oligomeric pores remain elusive. To characterize how Bak forms pores during apoptosis, we investigated its oligomerization under native conditions using blue native PAGE. We report that, in a healthy cell, inactive Bak is either monomeric or in a large complex involving VDAC2. Following an apoptotic stimulus, activated Bak forms BH3:groove homodimers that represent the basic stable oligomeric unit. These dimers multimerize to higher-order oligomers via a labile interface independent of both the BH3 domain and groove. Linkage of the α6:α6 interface is sufficient to stabilize higher-order Bak oligomers on native PAGE, suggesting an important role in the Bak oligomeric pore. Mutagenesis of the α6 helix disrupted apoptotic function because a chimera of Bak with the α6 derived from Bcl-2 could be activated by truncated Bid (tBid) and could form BH3:groove homodimers but could not form high molecular weight oligomers or mediate cell death. An α6 peptide could block Bak function but did so upstream of dimerization, potentially implicating α6 as a site for activation by BH3-only proteins. Our examination of native Bak oligomers indicates that the Bak apoptotic pore forms by the multimerization of BH3:groove homodimers and reveals that Bak α6 is not only important for Bak oligomerization and function but may also be involved in how Bak is activated by BH3-only proteins.


Journal of Experimental Medicine | 2014

The BTB-ZF transcription factor Zbtb20 is driven by Irf4 to promote plasma cell differentiation and longevity

Stéphane Chevrier; Dianne Emslie; Wei Shi; Tobias Kratina; Cameron J. Wellard; Alexander Karnowski; Erdem Erikci; Gordon K. Smyth; Kamal Chowdhury; David M. Tarlinton; Lynn M. Corcoran

Zbtb20 facilitates terminal differentiation of B cells into antibody-secreting cells, and its expression is dependent on Irf4 and independent of Blimp1.


Immunology and Cell Biology | 2014

Germinal center-independent, IgM-mediated autoimmunity in sanroque mice lacking Obf1.

Stéphane Chevrier; Tobias Kratina; Dianne Emslie; Alexander Karnowski; Lynn M. Corcoran

Mice homozygous for a point mutation in the Rc3h1 gene encoding Roquin1, designated sanroque mice, develop a severe antibody‐mediated autoimmune condition. The disease is T‐cell intrinsic, exacerbated by macrophage‐intrinsic defects and driven by excessive T follicular helper cell generation and spontaneous germinal centre (GC) formation. This culminates in abnormally high numbers of plasma cells secreting high‐affinity autoreactive immunoglobulin G (IgG). Obf1 is a transcriptional co‐activator required for normal T‐cell‐dependent antibody responses, and it is essential for GC formation under all circumstances so far tested. We crossed sanroque mice with Obf1‐null mice to determine whether the hyperactivity of sanroque T cells could drive Obf1−/− B cells to differentiate to GC B cells, or conversely, if Obf1 loss would prevent sanroque‐mediated autoimmune disease. Surprisingly, while sanroque/Obf1−/− mice did not form GC, they still developed autoimmune disease and succumbed even more rapidly than did sanroque mice. The disease was mediated by autoreactive IgM, which may have been derived from a pre‐existing population of autoreactive B cells in the Obf1−/− mice responding to the over‐exuberant activity of sanroque CD4 cells.


Frontiers in Immunology | 2014

Oct2 and Obf1 as Facilitators of B:T Cell Collaboration during a Humoral Immune Response

Lynn M. Corcoran; Dianne Emslie; Tobias Kratina; Wei Shi; Susanne Hirsch; Nadine Taubenheim; Stéphane Chevrier

The Oct2 protein, encoded by the Pou2f2 gene, was originally predicted to act as a DNA binding transcriptional activator of immunoglobulin (Ig) in B lineage cells. This prediction flowed from the earlier observation that an 8-bp sequence, the “octamer motif,” was a highly conserved component of most Ig gene promoters and enhancers, and evidence from over-expression and reporter assays confirmed Oct2-mediated, octamer-dependent gene expression. Complexity was added to the story when Oct1, an independently encoded protein, ubiquitously expressed from the Pou2f1 gene, was characterized and found to bind to the octamer motif with almost identical specificity, and later, when the co-activator Obf1 (OCA-B, Bob.1), encoded by the Pou2af1 gene, was cloned. Obf1 joins Oct2 (and Oct1) on the DNA of a subset of octamer motifs to enhance their transactivation strength. While these proteins variously carried the mantle of determinants of Ig gene expression in B cells for many years, such a role has not been borne out for them by characterization of mice lacking functional copies of the genes, either as single or as compound mutants. Instead, we and others have shown that Oct2 and Obf1 are required for B cells to mature fully in vivo, for B cells to respond to the T cell cytokines IL5 and IL4, and for B cells to produce IL6 normally during a T cell dependent immune response. We show here that Oct2 affects Syk gene expression, thus influencing B cell receptor signaling, and that Oct2 loss blocks Slamf1 expression in vivo as a result of incomplete B cell maturation. Upon IL4 signaling, Stat6 up-regulates Obf1, indirectly via Xbp1, to enable plasma cell differentiation. Thus, Oct2 and Obf1 enable B cells to respond normally to antigen receptor signals, to express surface receptors that mediate physical interaction with T cells, or to produce and respond to cytokines that are critical drivers of B cell and T cell differentiation during a humoral immune response.


Cancer Cell | 2016

Id2 and E proteins orchestrate the initiation and maintenance of MLL-rearranged acute myeloid leukemia

Margherita Ghisi; Lev Kats; Frederick Masson; Jason Li; Tobias Kratina; Eva Vidacs; Omer Gilan; Maria A. Doyle; Andrea Newbold; Jessica E. Bolden; Kirsten Fairfax; Carolyn A. de Graaf; Matthew Firth; Johannes Zuber; Ross A. Dickins; Lynn M. Corcoran; Mark A. Dawson; Gabrielle T. Belz; Ricky W. Johnstone

E proteins and their antagonists, the Id proteins, are transcriptional regulators important for normal hematopoiesis. We found that Id2 acts as a key regulator of leukemia stem cell (LSC) potential in MLL-rearranged acute myeloid leukemia (AML). Low endogenous Id2 expression is associated with LSC enrichment while Id2 overexpression impairs MLL-AF9-leukemia initiation and growth. Importantly, MLL-AF9 itself controls the E-protein pathway by suppressing Id2 while directly activating E2-2 expression, and E2-2 depletion phenocopies Id2 overexpression in MLL-AF9-AML cells. Remarkably, Id2 tumor-suppressive function is conserved in t(8;21) AML. Low expression of Id2 and its associated gene signature are associated with poor prognosis in MLL-rearranged and t(8;21) AML patients, identifying the Id2/E-protein axis as a promising new therapeutic target in AML.


Immunology and Cell Biology | 2017

IL4 and IL21 cooperate to induce the high Bcl6 protein level required for germinal center formation

Stéphane Chevrier; Tobias Kratina; Dianne Emslie; David M. Tarlinton; Lynn M. Corcoran

Bcl6 (B‐cell lymphoma 6) is a transcriptional repressor and critical mediator of the germinal center reaction during a T‐cell‐dependent antibody response, where it enables somatic hypermutation of immunoglobulin genes and inhibits terminal differentiation via repression of Blimp1. It can also contribute to the development of diffuse large B‐cell lymphoma when expressed inappropriately. Bcl6 regulation is mediated both at the transcriptional and post‐transcriptional levels, and in particular a strong signal through the B‐cell receptor causes rapid proteasomal degradation of Bcl6. Despite the importance of Bcl6 in both immunity and cancer, little is known about how other extrinsic factors regulate Bcl6 in B cells. Here we show that Bcl6 is indeed highly unstable in B cells after a B‐cell receptor (BCR) signal, but that the T‐cell‐derived cytokines interleukin 4 (IL4) and IL21 counteract BCR‐mediated degradation, preserving Bcl6 protein levels. Stat6, downstream of IL4, can induce Bcl6 transcription directly. In vivo, B‐cell intrinsic loss of IL4 or IL21 signaling reduces the magnitude or duration of the GC response, respectively, while their combined loss almost completely eliminates the GC response. This work provides key insights into the effect mediated by T‐follicular helper cytokines on Bcl6 regulation.

Collaboration


Dive into the Tobias Kratina's collaboration.

Top Co-Authors

Avatar

Grant Dewson

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Colin Hockings

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Dianne Emslie

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Stéphane Chevrier

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

David L. Vaux

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Jerry M. Adams

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

John Silke

University of Melbourne

View shared research outputs
Top Co-Authors

Avatar

Paul G. Ekert

Royal Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge